Neurocrine Biosciences
NBIX
267 hedge funds and large institutions have $7.29B invested in Neurocrine Biosciences in 2017 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 82 increasing their positions, 93 reducing their positions, and 21 closing their positions.
210% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 21
24% more capital invested
Capital invested by funds: $5.88B → $7.29B (+$1.41B)
20% more funds holding
Funds holding: 223 → 267 (+44)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
2.62% less ownership
Funds ownership: 108.79% → 106.18% (-2.6%)
12% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 93
22% less call options, than puts
Call options by funds: $30.8M | Put options by funds: $39.6M
Top Buyers
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$66.1M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$31M |
| 3 |
Millennium Management
New York
|
+$28.5M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$26.5M |
| 5 |
Renaissance Technologies
New York
|
+$26.4M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$66.6M |
| 2 |
HM
HealthCor Management
New York
|
-$38.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$37.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$32.8M |
| 5 |
State Street
Boston,
Massachusetts
|
-$32M |
NBIX Hedge Fund Activity: Q4 2017 in Review
267 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2017, worth a combined $7.29B — up 24% from $5.88B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new NBIX positions and 21 closed out — a net gain of 44 holders — while 82 added to existing stakes and 93 trimmed.
The largest buyer was Artisan Partners, adding an estimated $66.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $66.6M.
- 267 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2017, up from 223 in Q3 2017.
- Funds reported $7.29B of Neurocrine Biosciences stock for Q4 2017, up 24% quarter-over-quarter.
- 65 funds opened new Neurocrine Biosciences positions in Q4 2017 and 21 closed out, a net change of +44 holders.
- The largest Neurocrine Biosciences buyer in Q4 2017 was Artisan Partners, an estimated $66.1M added.
- The largest Neurocrine Biosciences seller in Q4 2017 was T. Rowe Price Associates, an estimated $66.6M sold.
Based on aggregated 13F filings for Q4 2017.